Assay to measure the potency of receptor-ligand interactions in nanomedicines
OwnerPedro SANTAMARIAinventor
Life of this patent
Estimating the term…
Abstract
Described herein, is an isolated cell comprising a recombinant T cell receptor (TCR) and a TCR-pathway-dependent reporter, wherein the recombinant T cell receptor is specific for a disease-relevant antigen bound to an MHC molecule. Also described are methods of use for the isolated cell as an assay to determine the function or potency of a peptide-major histocompatibility complex (pMHC) coupled to a nanoparticle (pMHC-NP) that can be used as a medicine for treating an autoimmune disease or cancer.
Claims34
1-48. (canceled)
An in vitro method for assaying agonistic activity of a nanomedicine, wherein the nanomedicine comprises a nanoparticle coupled to a construct comprising a disease-relevant antigen bound to a major histocompatibility (MHC) molecule, the method comprising:
- a) contacting the nanomedicine with a cell comprising:
- a recombinant T cell receptor (TCR) comprising a TCR alpha chain and a TCR beta chain;
- and
- a T cell receptor-pathway-dependent reporter, wherein the recombinant T cell receptor is specific for the disease-relevant antigen bound to the MHC molecule coupled to the nanoparticle;
- and
- b) detecting a signal produced by the T cell receptor-pathway-dependent reporter.
(canceled)
Dependencies are inferred from the claim text.